Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The Pharma Letter18h
New duvakitug data reinforce best-in-class potential
French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...
Trump tells Big Pharma to bring production home or face tariffs: Bloomberg News
President Donald Trump has warned a group of major U.S. drugmakers that his administration is set to impose tariffs on pharmaceutical goods, and they should start moving their manufacturing businesses ...
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...
SaverOne 2014 Ltd.: SaverOne Implements Change in Ratio of Shares to ADSs to Meet Nasdaq Minimum Bid Price Requirement
SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), On February 20, 2025, SaverOne 2014 Ltd. received a letter from the Listing Qualifications Department ...
Santé log11h
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
About duvakitug Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 ...